Newsfeeds - Spark Newswire

4 minute read

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank

Today, 1:06 PM

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the company’s Silicon Valley Bank.

AMBA

1 minute read

News

Kymera Therapeutics Says Holding ~$2.2M Of Cash Balance At SVB

By Benzinga Newsdesk

Today, 1:06 PM

-SEC Filing

KYMR

1 minute read

Analyst Ratings

Analyst Ratings for Kymera Therapeutics

By Benzinga Insights

Today, 1:06 PM

Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: Bullish Somewhat Bullish Indifferent…

KYMR

1 minute read

HC Wainwright & Co. Reiterates Buy on Kymera Therapeutics, Maintains $85 Price Target

By Benzinga Newsdesk

Today, 1:06 PM

HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $85 price target.

KYMR

17 minute read

Earnings

Earnings Scheduled For February 23, 2023

By Benzinga Insights

Today, 1:06 PM

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

AAOI

1 minute read

Goldman Sachs Maintains Buy on Kymera Therapeutics, Raises Price Target to $52

By Benzinga Newsdesk

Today, 1:06 PM

Goldman Sachs analyst Chris Shibutani maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $40 to $52.

KYMR

1 minute read

SVB Leerink Maintains Market Perform on Kymera Therapeutics, Raises Price Target to $31

By Benzinga Newsdesk

Today, 1:06 PM

SVB Leerink analyst Mike Kratky maintains Kymera Therapeutics (NASDAQ:KYMR) with a Market Perform and raises the price target from $26 to $31.

KYMR

4 minute read

Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 1:06 PM

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

ARQQ

1 minute read

Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial

By Vandana Singh

Today, 1:06 PM

Kymera Therapeutics Inc (NASDAQ:KYMR) announced clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 trial in hidradenitis…

KYMR

1 minute read

Kymera Announces Results From Phase 1 Clinical Trial Evaluating KT-474 In Patients With HS And AD And Sanofi’s Decision To Advance KT-474 Into Phase 2 Clinical Trials

By Bill Haddad

Today, 1:06 PM

KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety

KYMR